Brewer Jerry D, Shanafelt Tait D, Cerhan James R, Call Timothy G, Weaver Amy L, Otley Clark C
*Division of Dermatologic Surgery, Mayo Clinic, Rochester, Minnesota; †Division of Hematology, Mayo Clinic, Rochester, Minnesota; ‡Division of Epidemiology, Mayo Clinic, Rochester, Minnesota; §Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota; ‖Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, Minnesota.
Dermatol Surg. 2016 Jan;42 Suppl 1:S32-9. doi: 10.1097/DSS.0000000000000520.
To quantify the behavior of dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), Kaposi sarcoma (KS), and sebaceous carcinoma (SC) in patients with a history of non-Hodgkin lymphoma (NHL).
Subjects with a diagnosis of DFSP, MFH, KS, or SC between 1990 and 2006 were identified in the Surveillance, Epidemiology, and End Results Program database. For each skin cancer type, the standardized mortality ratio (SMR) for death due to any cause and death due to skin cancer was estimated.
From 1990 through 2006, 25,357 skin cancers were identified: 4,192 DFSP, 6,412 MFH, 10,543 KS, and 4,222 SC. For patients with a history of non-CLL NHL, SMRs for death due to any cause were 1.45 (95% confidence interval [CI], 1.03-2.04; p = 0.04) for MFH, 2.90 (95% CI, 2.50-3.36; p < 0.001) for KS, and 3.25 (95% CI, 1.84-5.75; p < 0.001) for SC and SMRs for death due to skin cancer were 0.55 (95% CI, 0.23-1.31; p = 0.18) for MFH, 2.93 (95% CI, 2.49-3.43; p < 0.001) for KS, and 4.07 (95% CI, 1.28-12.94; p < 0.001) for SC.
Among patients with KS and SC, patients with a history of non-CLL NHL have a greater risk of overall and cause-specific death than expected.
量化有非霍奇金淋巴瘤（NHL）病史患者中隆突性皮肤纤维肉瘤（DFSP）、恶性纤维组织细胞瘤（MFH）、卡波西肉瘤（KS）和皮脂腺癌（SC）的发病情况。
在监测、流行病学和最终结果计划数据库中识别出1990年至2006年间诊断为DFSP、MFH、KS或SC的患者。对于每种皮肤癌类型，估计任何原因导致的死亡以及皮肤癌导致的死亡的标准化死亡比（SMR）。
从1990年到2006年，共识别出25357例皮肤癌：4192例DFSP、6412例MFH、10543例KS和4222例SC。对于有非慢性淋巴细胞白血病（CLL）NHL病史的患者，MFH因任何原因导致的死亡的SMR为1.45（95%置信区间[CI]，1.03 - 2.04；p = 0.04），KS为2.90（95% CI，2.50 - 3.36；p < 0.001），SC为3.25（95% CI，1.84 - 5.75；p < 0.001）；MFH因皮肤癌导致的死亡的SMR为0.55（95% CI，0.23 - 1.31；p = 0.18），KS为2.93（95% CI，2.49 - 3.43；p < 0.001），SC为4.07（95% CI，1.28 - 12.94；p < 0.001）。
在患有KS和SC的患者中，有非CLL NHL病史的患者总体死亡和特定病因死亡风险高于预期。
